Condition: IgA Nephropathy · Sponsor: Biohaven Therapeutics Ltd.
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
This description comes directly from the study's public registry record.
Chief Medical Officer · 203-404-0410 · clinicaltrials@biohavenpharma.com
Always discuss trial participation with your own doctor first.
| Site-001 | Farmington, Connecticut, United States | Recruiting |
| Site-003 | Miami Lakes, Florida, United States | Recruiting |
| Site-011 | Miami Lakes, Florida, United States | Recruiting |
| Site-013 | Orlando, Florida, United States | Recruiting |
| Site-005 | Pembroke Pines, Florida, United States | Recruiting |
| Site-008 | Lawrenceville, Georgia, United States | Recruiting |
| Site-009 | Hinsdale, Illinois, United States | Recruiting |
| Site-012 | Indianapolis, Indiana, United States | Recruiting |
| Site-015 | Shelby, Michigan, United States | Recruiting |
| Site-006 | Chesterfield, Missouri, United States | Recruiting |
| Site-002 | Dakota Dunes, South Dakota, United States | Recruiting |
| Site-014 | Houston, Texas, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07054684